Marksans Pharma Ltd

Marksans Pharma Ltd recorded a robust intraday performance on 3 Feb 2026, surging to a day’s high of Rs 186.6, marking a 13.54% increase from the previous close. This strong upward momentum outpaced both its sector and the broader market, reflecting notable trading activity and positive price action throughout the session.

Marksans Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Marksans Pharma Ltd has touched a new 52-week low of Rs.157.25 today, marking a significant decline in its stock price amid broader market fluctuations and sectoral pressures. This fresh low reflects ongoing challenges faced by the company in maintaining growth momentum and investor confidence over the past year.

Marksans Pharma Ltd’s shares declined to a fresh 52-week low of Rs.159.15 on 27 Jan 2026, marking a significant downturn amid broader market resilience. The stock has underperformed its sector and major indices, reflecting ongoing concerns about its recent financial performance and investor participation.

Marksans Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a modest day gain of 0.62%, the stock’s broader technical landscape suggests caution for investors amid mixed signals from MACD, RSI, and moving averages.

Marksans Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Marksans Pharma Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent upgrade from a Hold to a Sell rating by MarketsMOJO on 7 July 2025, the stock’s price action and technical parameters suggest a cautiously evolving outlook for investors in the Pharmaceuticals & Biotechnology sector.

Marksans Pharma Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 07 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Marksans Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade from a Hold to a Sell rating reflects deteriorating market sentiment, as technical parameters such as moving averages, MACD, and Bollinger Bands align to suggest further downside risk.

Marksans Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook.

Marksans Pharma has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters amid a subdued performance environment. The pharmaceutical company’s recent assessment highlights evolving perspectives on its quality, valuation, financial trends, and technical outlook, set against a backdrop of sector pressures and market underperformance.

Marksans Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor perception. This adjustment highlights evolving views on the company’s financial trends, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector.

Marksans Pharma Ltd., a Mumbai-based pharmaceutical formulation manufacturer, reported a consolidated net profit of ₹98.25 crores for Q2 FY26, marking a robust 68.47% quarter-on-quarter surge from ₹58.32 crores in Q1 FY26. However, the year-on-year picture remains subdued, with profits growing just 1.58% from ₹96.72 crores in Q2 FY25. The ₹8,712 crore market capitalisation company's shares have faced persistent selling pressure, declining 37.30% over the past year despite the recent quarterly uptick, as foreign institutional investors continue reducing their stake.

Marksans Pharma has experienced recent stock price fluctuations, currently priced at 187.00. The company shows mixed technical indicators, with some suggesting bullish momentum while others indicate bearish trends. Despite recent declines in year-to-date and one-year returns, the stock has demonstrated substantial growth over three and five years.